Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

Mark Lebwohl1, Richard G. Langley2, Cde Pau3, Liu4, Kristian Reich5, Peter van der Kley5, Liu6, Yvonne America7, Bruce Queener8, Paul Gleeson9
1Ludwig Institute of Skin and Blood Diseases, Mount Sinai, New York, NY, USA; 2Department of Dermatology, Portland, Oregon; 3Paul Sabatier University, Toulouse, France; 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 5Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands; 7Yale University School of Medicine, New Haven, Connecticut, USA; 8Division of Dermatology, Department of Medicine, Dalhousie University Medical Center, Halifax, Canada; 9Department of Dermatology, University of the Witwatersrand, Johannesburg, South Africa

Synopsis
• The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey provided valuable data on quality of life and unmet needs in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA).1,2
• The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP.

Objective
• The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP.

Methods
• UPLIFT: Quantitative online survey from March 2, 2020, to June 3, 2020; 4,729 participants (473 dermatologists, 450 rheumatologists, 3,808 patients)
• MAPP: Telephone survey from June 12 to August 20121,2; 4,207 participants (391 dermatologists, 390 rheumatologists, 3,426 patients)

Results

In both UPLIFT and MAPP:
• Most patients had PsO
• Similar proportions of patients reported having limited skin involvement (body surface area [BSA] ≤3 palms)

In UPLIFT, 58% of patients with limited BSA rated their current PsO symptoms as moderate or severe
• Many had PsO involvement in special areas (scalp, face, palms and/or soles, nails, genitals) and were not receiving treatment

In UPLIFT, 60% of PsO patients with limited BSA and involvement in ≥1 area reported their current disease as moderate or severe

More than half of UPLIFT patients with limited BSA (≤3 palms) perceived their PsO as moderate or severe

In both surveys, high proportions of patients reported that they were not currently receiving treatment

Conclusion
• More than half of patients with limited skin involvement reported their current disease as moderate or severe, had PsO involvement in special areas, and were receiving topicals or no treatment, suggesting a persistent unmet need in this patient population
• In MAPP vs. UPLIFT, the proportion of patients describing their disease as moderate to severe on systematic treatment remained relatively low despite the higher number of available treatment options
• Further research is needed to better understand why a significant proportion of patients with limited skin involvement and PsO in special areas perceive their current disease as moderate or severe but do not receive systemic treatment

Table 1: Patients’ self-reported PsO severity according to BSA

<table>
<thead>
<tr>
<th>Group</th>
<th>UPLIFT</th>
<th>MAPP</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤3 palms</td>
<td>38</td>
<td>53</td>
</tr>
<tr>
<td>4–10 palms</td>
<td>25</td>
<td>41</td>
</tr>
<tr>
<td>&gt;10 palms</td>
<td>23</td>
<td>37</td>
</tr>
</tbody>
</table>

In UPLIFT, 51% were receiving topicals or no treatment

DISCLOSURES AND FUNDING STATEMENT

The authors report the following relevant financial relationships:

Lebwohl: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB—honoraria and speaking fees.
Langley: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB—honoraria and speaking fees.
Pau: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
Reich: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
van der Kley: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
Kley: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
America: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
Queener: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.
Gleeson: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis—consultant and/or lecturer.

REFERENCES


FUNDING STATEMENT

This work was supported by Amgen Inc., AbbVie, Biogen, Boehringer Ingelheim, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, which provided support to the investigators, study sites, and study monitoring. The UPLIFT investigators had full access to all the data in the study and had final responsibility for the decision to submit for publication.

© 2021 Amgen Inc.